Ligands of Immunopharmacology

TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopeniaIn VivoThe thrombopoietin (TPO) receptor

TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopeniaIn VivoThe thrombopoietin (TPO) receptor

TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopeniaIn VivoThe thrombopoietin (TPO) receptor

TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopeniaIn VivoThe thrombopoietin (TPO) receptor

TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity ( K D =95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function.In VitroTPP-1 binds to PD-L1 with high

TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity ( K D =95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function.In VitroTPP-1 binds to PD-L1 with high

TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity ( K D =95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function.In VitroTPP-1 binds to PD-L1 with high

TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity ( K D =95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function.In VitroTPP-1 binds to PD-L1 with high

VAF347 is a cell permeable and highly affinity aryl hydrocarbon receptor (AhR) agonist and induces AhR signaling. VAF347 inhibits the development of CD14 + CD11b + monocytes from granulo-monocytic (GM stage) precursors. VAF347 has anti-inflammatory

VAF347 is a cell permeable and highly affinity aryl hydrocarbon receptor (AhR) agonist and induces AhR signaling. VAF347 inhibits the development of CD14 + CD11b + monocytes from granulo-monocytic (GM stage) precursors. VAF347 has anti-inflammatory

VAF347 is a cell permeable and highly affinity aryl hydrocarbon receptor (AhR) agonist and induces AhR signaling. VAF347 inhibits the development of CD14 + CD11b + monocytes from granulo-monocytic (GM stage) precursors. VAF347 has anti-inflammatory

VAF347 is a cell permeable and highly affinity aryl hydrocarbon receptor (AhR) agonist and induces AhR signaling. VAF347 inhibits the development of CD14 + CD11b + monocytes from granulo-monocytic (GM stage) precursors. VAF347 has anti-inflammatory